StreetInsider.com News Articles

Legend Biotech to present LB2501 in vivo CAR-T data at EHA conference

Tue, 02 Jun 2026 09:30:19 -0400

Legend Biotech Corporation (NASDAQ: LEGN) will present Phase 1 clinical data for its investigational therapy LB2501 at the European Hematology Association Congress from June 11-14, 2026, in Stockholm, Sweden.

LB2501 is designed as an in vivo CAR-T therapy that targets both CD19 and CD20 proteins for treating relapsed or refractory B-cell non-Hodgkin lymphoma. The therapy generates CAR-T cells directly within patients following a single intravenous infusion, eliminating the need for cell manufacturing and lymphodepletion.

The ongoing Phase 1 study included 12 patients across two dose levels as of April 1, 2026. In the dose level 2 cohort, which had a median follow-up

Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

Tue, 02 Jun 2026 09:30:00 -0400

Promising Phase 1 data for LB2501, a potential first‑in‑class CD19/CD20 dual‑targeting in vivo CAR-T therapy, as an off-the-shelf, single-infusion treatment for B‑cell malignancies
An ORR of 100% (6/6) was observed in the dose level 2 cohort, including CR rate of 83.3% (5/6) in patients with relapsed/ refractory NHL
Data demonstrate robust in vivo CAR-T expansion without lymphodepleting chemotherapy
Favorable safety profile: no DLTs, no SAEs, no ICANS, CRS <Grade 2

BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader

Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

Tue, 02 Jun 2026 09:30:00 -0400

Promising Phase 1 data for LB2501, a potential first‑in‑class CD19/CD20 dual‑targeting in vivo CAR-T therapy, as an off-the-shelf, single-infusion treatment for B‑cell malignancies
An ORR of 100% (6/6) was observed in the dose level 2 cohort, including CR rate of 83.3% (5/6) in patients with relapsed/ refractory NHL
Data demonstrate robust in vivo CAR-T expansion without lymphodepleting chemotherapy
Favorable safety profile: no DLTs, no SAEs, no ICANS, CRS <Grade 2

BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader

Form 6-K Legend Biotech Corp For: Jun 02

Tue, 02 Jun 2026 09:30:00 -0400

si-local-file:///var/storage/secattach/20260602/26588999.html

Form 6-K Legend Biotech Corp For: Jun 02

Tue, 02 Jun 2026 09:30:00 -0400

si-local-file:///var/storage/secattach/20260602/26588999.html

Legend Biotech presents early solid tumor data for LB2102 at ASCO 2026

Mon, 01 Jun 2026 10:00:45 -0400

Legend Biotech Corporation (NASDAQ: LEGN) presented first-in-human clinical data for LB2102, an investigational DLL3-targeted CAR-T cell therapy for patients with relapsed or refractory small cell lung cancer and large-cell neuroendocrine carcinoma at the 2026 American Society of Clinical Oncology Annual Meeting.

The Phase 1 study enrolled 20 patients with advanced disease. LB2102 demonstrated an overall objective response rate of 20% and disease control rate of 70% across all dose levels. At higher dose levels (≥3), the therapy showed improved efficacy with an objective response rate of 28.6% and disease control rate of 78.6%. The median duration of response was 6.5 months,

Legend Biotech presents early solid tumor data for LB2102 at ASCO 2026

Mon, 01 Jun 2026 10:00:45 -0400

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

Mon, 01 Jun 2026 10:00:00 -0400

LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients
Responses observed at higher dose levels of LB2102 with an ORR of 28.6% and a DCR of 78.6%, with durable responses seen in some patients
New CARVYKTI^®data continue to support durable efficacy and a consistent safety profile in multiple myeloma

BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced first-in-human clinical data for LB2102, its investigational DLL3-targeted CAR-T cell

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

Mon, 01 Jun 2026 10:00:00 -0400

LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients
Responses observed at higher dose levels of LB2102 with an ORR of 28.6% and a DCR of 78.6%, with durable responses seen in some patients
New CARVYKTI^®data continue to support durable efficacy and a consistent safety profile in multiple myeloma

Form 6-K Legend Biotech Corp For: Jun 01

Mon, 01 Jun 2026 10:00:00 -0400

si-local-file:///var/storage/secattach/20260601/26580759.html

Form 6-K Legend Biotech Corp For: Jun 01

Mon, 01 Jun 2026 10:00:00 -0400

si-local-file:///var/storage/secattach/20260601/26580759.html

RBC Capital on Legend Biotech Corp. (LEGN): 'We remain buyers'

Mon, 01 Jun 2026 07:48:07 -0400

RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $64.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).

The analyst commented: "Tidbits From Investor Event: Pointing Carvykti Toward Use in Earlier Setting; On Sunday, LEGN hosted an analyst event discussing Carvykti's position in the myeloma market. We agree that Carvykti is a very attractive therapy, with a compelling near-cure narrative, and both the clinical data and biology support a rationale for success in earlier lines. While safety and competition will remain overhangs, we think a better understanding of movement disorder causes (e.g. insufficient bridging) can continue to improve the

H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)

Mon, 01 Jun 2026 06:58:27 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $50.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).

The analyst commented: 'Legend hosted an ASCO event yesterday focused on the CARTITUDE program and CARVYKTI (cilta-cel), featuring three multiple myeloma (MM) KOLs: Dr. Binod Dhakal of the Medical College of Wisconsin; Dr. Doris Hansen of Moffitt Cancer Center in Tampa, FL; and Dr. Surbhi Sidana of Stanford University. The discussion centered on CARVYKTI’s long-term treatment-free remission data, the case for first-relapse use, and practical safety management with effective bridging. The KOLs were aligned that CARVYKTI should be discussed at first

H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)

Wed, 27 May 2026 06:45:09 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $50.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).

The analyst commented: "Legend’s newly posted China Phase 1 study of LVIVO-TaVec400 adds an autoimmune lane to its in vivo CAR-T platform. The study is evaluating a BCMA-targeted in vivo CAR-T across relapsed/refractory autoimmune diseases, including systemic lupus erythematosus (SLE), IgG4-related disease, progressive multiple sclerosis (PMS), and myasthenia gravis (MG), in a 44-patient open-label dose-escalation/dose-expansion trial. Legend confirmed to us that this is a BCMA-targeted autoimmune construct, distinct from the oncology in vivo CAR-T construct where we think investors could see

Legend Biotech Announces Presentations at ASCO 2026

Thu, 21 May 2026 17:00:00 -0400

Preliminary results from Phase 1 data for LB2102 to reinforce early evidence of activity in solid tumors in a rapid oral presentation
New data from the CARTITUDE-4 study to highlight a cytogenetic subgroup analysis of patients who responded to bridging therapy will be featured in a poster presentation
Company to host on-site investor relations event and webcast on Sunday, May 31, at 6:15 p.m. CT